Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT).
EGFR T790M mutation
advanced non-small cell lung cancer
real-world retrospective study
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
17 08 2022
17 08 2022
Historique:
received:
21
06
2022
revised:
03
08
2022
accepted:
11
08
2022
entrez:
25
8
2022
pubmed:
26
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
The targeted therapy with tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor mutation (EGFRm) in advanced non-small cell lung cancer (NSCLC) changed the treatment paradigm. REFLECT study (NCT04031898) explored
Identifiants
pubmed: 36005198
pii: curroncol29080460
doi: 10.3390/curroncol29080460
pmc: PMC9406426
doi:
Substances chimiques
Protein Kinase Inhibitors
0
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Banques de données
ClinicalTrials.gov
['NCT04031898']
Types de publication
Clinical Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5833-5845Références
Oncotarget. 2016 Aug 30;7(35):56998-57010
pubmed: 27486770
Cancer Discov. 2014 Sep;4(9):1046-61
pubmed: 24893891
J Oncol Pharm Pract. 2021 Jun 13;:10781552211020798
pubmed: 34120514
Cureus. 2020 Dec 17;12(12):e12128
pubmed: 33489541
Int J Clin Exp Pathol. 2013 Nov 15;6(12):2800-12
pubmed: 24294366
ESMO Open. 2020 Nov;5(6):e001011
pubmed: 33148621
Lung Cancer. 2020 Feb;140:71-79
pubmed: 31884129
Oncotarget. 2016 Nov 29;7(48):78985-78993
pubmed: 27738317
Lung Cancer. 2019 Nov;137:113-122
pubmed: 31568888
Expert Rev Anticancer Ther. 2019 Jun;19(6):431-435
pubmed: 30950666
Cancer Res Treat. 2018 Oct;50(4):1294-1303
pubmed: 29334606
Ther Adv Med Oncol. 2021 Mar 24;13:1758835921996509
pubmed: 34408792
Curr Oncol Rep. 2019 Feb 26;21(3):21
pubmed: 30806814
Drugs Real World Outcomes. 2021 Dec;8(4):537-545
pubmed: 34533784
J Clin Oncol. 2018 Aug 28;:JCO2018783118
pubmed: 30153097
Nat Rev Dis Primers. 2015 May 21;1:15009
pubmed: 27188576
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
J Clin Oncol. 2018 Mar 20;36(9):841-849
pubmed: 28841389
Radiol Oncol. 2014 Apr 25;48(2):173-83
pubmed: 24991207
Ann Oncol. 2016 Sep;27(suppl 5):v1-v27
pubmed: 27664245
BMC Cancer. 2020 Apr 28;20(1):356
pubmed: 32345265
Ann Oncol. 2019 Aug 1;30(8):1356-1369
pubmed: 31147719
Future Oncol. 2021 Feb;17(4):471-486
pubmed: 33094641
Drugs Real World Outcomes. 2021 Jun;8(2):141-152
pubmed: 33710523
Ann Oncol. 2020 Nov;31(11):1581-1582
pubmed: 32798688
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
J Clin Oncol. 2018 Sep 10;36(26):2702-2709
pubmed: 30059262
Oncologist. 2022 Mar 4;27(2):87-e115
pubmed: 35641222
Lung Cancer. 2018 Jul;121:12-17
pubmed: 29858020
Ther Adv Med Oncol. 2021 Nov 29;13:17588359211059874
pubmed: 35173817
Cancers (Basel). 2019 Jul 01;11(7):
pubmed: 31266248
Oncologist. 2018 Dec;23(12):e152-e158
pubmed: 30076278
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Drugs Today (Barc). 2016 Oct;52(10):561-568
pubmed: 27910964
Lung Cancer. 2015 Apr;88(1):108-11
pubmed: 25682925